Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years [Phase 2]

View source ↗

Summary

Pfizer's FSME IMMUN NEW completed a Phase 2 follow-up study (Study 205) in children aged 6 to 16 years for tick-borne encephalitis. The trial status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 2 | Status: COMPLETED